Shots:

• The company has submitted the IND to the US FDA for evaluating its re-purposed drug NP-120 (Ifenprodil) in P-IIb/III study as a potential therapeutic treatment against COVID-19. The study will begin as a P-IIb study in 100 patients and with positive preliminary data- the clinical trial will move directly from a P-IIb into P-III study
• The study will evaluate the safety and efficacy of NP-120 (20mg- q3w for 2wks.) + SOC vs SOC in confirmed COVID-19 infected hospitalized patients. The company has received clearance in Canada and has also filed for ethics approval in Australia
• NP-120 is an NMDA receptor antagonist specifically targeting the NMDA-type subunit 2B (Glu2NB)- acts by preventing glutamate signaling. Algernon has filed new IP rights globally for NP-120 to treat respiratory diseases and is working to develop an injectable and slow-release formulation

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Algernon